Prothena Corporation PLC header image

Prothena Corporation PLC

PRTA

Equity

ISIN IE00B91XRN20 / Valor 20224443

NASDAQ (2025-03-13)
USD 14.07+1.52%

Prothena Corporation PLC
UMushroom community rating:

star star star star star
4.00 1 votes No rating yet
NegativeNeutralPositive

About company

Prothena Corporation PLC is a biotechnology firm focused on the late-stage clinical development of treatments for neurodegenerative and rare peripheral amyloid diseases. Leveraging its expertise in protein dysregulation, the company has developed a diverse pipeline of investigational therapies aimed at addressing the complex challenges of neurological dysfunction and misfolded proteins. Prothena's approach combines internal discovery with strategic collaborations across academia and the industry to advance its portfolio of novel therapeutic solutions. Founded from the legacy of Athena Neurosciences and established as an independent entity in December 2012, Prothena trades on the Nasdaq Global Select Market under the symbol "PRTA." The company's commitment to innovation is rooted in its history of significant scientific contributions, including discoveries that have advanced the understanding of Alzheimer’s disease and the development of FDA-approved treatments for multiple sclerosis.

Summarized from source with an LLMView SourceSector: Technology

Latest Results (10.01.2025):

Net Loss

For the third quarter of 2024, Prothena Corporation PLC reported a net loss of $59.0 million, compared to a net income of $21.9 million in the same quarter of 2023. For the first nine months of 2024, the net loss was $64.4 million, compared to a net loss of $79.6 million for the same period in 2023. The net loss per share was $1.10 for the third quarter and $1.20 for the first nine months of 2024.

Revenue

Prothena Corporation PLC reported total revenue of $1.0 million for the third quarter of 2024, a significant decrease from $84.9 million in the third quarter of 2023. For the first nine months of 2024, total revenue was $133.0 million, compared to $91.1 million for the same period in 2023. The revenue was primarily derived from collaboration revenue with Bristol Myers Squibb.

Research and Development Expenses

Research and development expenses for Prothena Corporation PLC totaled $50.7 million for the third quarter of 2024, down from $57.9 million in the same quarter of 2023. For the first nine months of 2024, R&D expenses were $172.3 million, up from $158.7 million for the same period in 2023. The changes were primarily due to variations in manufacturing and clinical trial expenses.

General and Administrative Expenses

General and administrative expenses for Prothena Corporation PLC were $16.8 million for the third quarter of 2024, slightly up from $16.6 million in the third quarter of 2023. For the first nine months of 2024, G&A expenses were $50.4 million, compared to $44.9 million for the same period in 2023. The increase was mainly due to higher personnel-related expenses.

Cash Position

As of September 30, 2024, Prothena Corporation PLC had $520.1 million in cash, cash equivalents, and restricted cash, with no debt. The company expects to end the year with approximately $468 million in cash, cash equivalents, and restricted cash, based on its financial guidance for 2024.

Summarized from source with an LLMView Source

Key figures

-50.8%1Y
-57.9%3Y
40.7%5Y

Performance

70.6%1Y
76.2%3Y
77.9%5Y

Volatility

Market cap

1744 M

Market cap (USD)

Daily traded volume (Shares)

379,193

Daily traded volume (Shares)

1 day high/low

15.25 / 14.66

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.00

1 votes
Performance:
starstarstarstarstar
3.00
Innovation:
starstarstarstarstar
4.00
Society:
starstarstarstarstar
5.00
Nature:
starstarstarstarstar
4.00
Daniel Bruggmann
Switzerland, 05 Mar 2025
star star star star star
Für unsere Gesundheit

EQUITIES OF THE SAME SECTOR

Exelixis Inc
Exelixis Inc Exelixis Inc Valor: 1069927
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.08%USD 36.80
UiPath Inc
UiPath Inc UiPath Inc Valor: 110831715
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-15.72%USD 9.97
Fabrinet
Fabrinet Fabrinet Valor: 3595304
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
10.79%USD 223.66
Parsons Corporation
Parsons Corporation Parsons Corporation Valor: 47481760
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.32%USD 56.65
GRENKE AG
GRENKE AG GRENKE AG Valor: 28741392
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-18.81%EUR 13.90
Apple Inc
Apple Inc Apple Inc Valor: 908440
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.36%USD 209.68
Meta Platforms Inc
Meta Platforms Inc Meta Platforms Inc Valor: 14917609
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-4.67%USD 590.64
Baidu Inc
Baidu Inc Baidu Inc Valor: 2231362
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.01%USD 94.26
Check Point Software Technologies Ltd
Check Point Software Technologies Ltd Check Point Software Technologies Ltd Valor: 494683
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.42%USD 214.90
Mercury Systems Inc
Mercury Systems Inc Mercury Systems Inc Valor: 847694
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
7.08%USD 45.08